CD8A and neoplasm: Preclinical evidence supports that moDCs in the tumor and DLN play a key role in CD8+ T cell activation and antitumor immunity after immunotherapy (46), and IFN-β signaling in tumor-infiltrating inflammatory monocytes has been associated with T cell expansion in patients who respond to immune checkpoint blockade (68).